secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0000950170-25-096438
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside explores strategic alternatives; all employees terminated, R&D paused
-------------------------------------------------------------------------------

- All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.
- Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.
- Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.
- No agreement reached; no timetable set; no assurance any transaction will occur.
- CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025096438/0000950170-25-096438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025096438/clsd-20250717.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-096438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer